MF-iPSCs were established using episomal vectors. (A) Experimental scheme for generating iPSCs from MF patient samples is shown. MF-iPSCs with integration-free episomal vectors from 3 different MF patients harboring JAK2 V617F, CALR type 1, and CALR type 2 mutations were established. (B) Expression of pluripotency markers including SSEA-4 and TRA-1-60 was confirmed by immunostaining. Scale bar, 200 μm. (C) Cells differentiated from MF-iPSCs were analyzed by flow cytometry for the presence of CD34⁺ and CD43⁺ hematopoietic cells. (D) JAK2 inhibitor (ruxolitinib) was used for validation of drug sensitivity of MF-HPCs harboring JAK2 V617F and CALR type 2 mutation. Results are means ± standard deviation (SD). N = 3, independent experiments. Analysis of variance (ANOVA) test: *P < .05, **P < .01, ***P < .001. (E) HSP.90 inhibitor (PU-H71) was used for validation of drug sensitivity of MF-HPCs harboring JAK2 V617F. Results are means ± SD. N = 2, independent experiments. Unpaired 2-tailed Student t test: *P < .05, **P < .01.